Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
Fadi TazaAlbert E HollerWei FuHao WangNabil AdraCostantine AlbanyRyan AshkarHeather H ChengAlexandra O SokolovaArchana M AgarwalAdam KesselAlan H BryceNellie NafissiPedro C BarataA Oliver SartorDiogo Assed BastosOren SmaletzJacob E BerchuckMary-Ellen TaplinRahul R AggarwalCora N SternbergPanagiotis J VlachostergiosAjjai S AlvaChristopher T SuCatherine Handy MarshallEmmanuel S AntonarakisPublished in: JCO precision oncology (2021)
PARP inhibitor efficacy is diminished in BRCA1- versus BRCA2-altered mCRPC. This is not due to an imbalance in germline mutations but might be related to more monoallelic mutations and/or concurrent TP53 alterations in the BRCA1 group.